Shanghai Model Organisms Center Earnings Call Summary
Earnings Call Summary
A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Shanghai Model Organisms Center Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Shanghai Model Organisms Center, Inc.
Shanghai Model Organisms Center, Inc.
688265
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. It offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, as well as spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine and viral infection receptor. The company also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and Cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system. In addition, it offers model customization including includes gene editing technology, such as ES cell targeting, CRISPR gene editing, and transgene; genetically engineered type model, which includes conventional and conditional knockout; KO first, knock-in, point mutation, conditional point mutation, humanization, targeted conditional overexpression, and random transgene; and surgery and preconditioning. Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene e...
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. It offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, as well as spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine and viral infection receptor. The company also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and Cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system. In addition, it offers model customization including includes gene editing technology, such as ES cell targeting, CRISPR gene editing, and transgene; genetically engineered type model, which includes conventional and conditional knockout; KO first, knock-in, point mutation, conditional point mutation, humanization, targeted conditional overexpression, and random transgene; and surgery and preconditioning. Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
